Editor's Note: Unlocking the Mystery of Pulmonary Hypertension
Pulmonary hypertension (PH) is a complex medical puzzle, leaving patients entangled in a web of symptoms and specialists. This month's cover story bravely tackles the challenge of explaining PH, a condition that often goes unrecognized and undertreated. But here's the catch: patients with PH often slip through the diagnostic net.
PH patients present with vague symptoms like fatigue, breathlessness, mild swelling, dizziness, chronic cough, and palpitations. These symptoms are frequently dismissed as signs of poor fitness or aging. But who should take the lead in managing these patients? Pulmonologists, cardiologists, surgeons—it's a dilemma! And the confusion doesn't end there.
The classification of PH itself is a tangled web. The WHO groups it into five categories, each with distinct causes. Group 1 is pulmonary arteriolar medial and intimal proliferation (PAH). Group 2 is linked to left heart disease and valve issues. Group 3 results from chronic lung disease and low oxygen levels. Group 4 is caused by recurrent small blood clots. And Group 5? Well, that's a mystery, with unknown causes.
An echocardiogram can be a helpful starting point, estimating pulmonary artery pressure and identifying structural issues. But for a definitive diagnosis, a right heart catheterization is required. This procedure also distinguishes between primary pulmonary artery issues (PAH) and secondary PH linked to left heart diseases (PH-LHD).
And now, the treatment conundrum. The cover story reveals a surprising twist: the 'obvious' first-line therapy for PH-LHD, pulmonary vasodilators, might actually be harmful. The cost of new drugs adds to the complexity. With no single, affordable treatment available, patients often require referral to specialized centers for interventional therapies.
But there's hope! New treatments are emerging, including pulmonary artery surgery and interventional balloon therapies. Sotatercept, a breakthrough drug, treats PAH by targeting cellular proliferation in the pulmonary arteries. Clinical trials showed impressive results, reducing pulmonary vascular resistance and leading to early trial termination due to multiple benefits.
This issue also features a review of PH and shunting in pregnancy, a must-read for understanding this unique patient group. And did you know that 'long' COVID may be linked to PH in some patients? Riociguat, a new drug, shows promise in reducing pulmonary artery pressure in these cases.
While the PH puzzle remains unsolved, advancements in treatment offer a glimmer of hope. But the question remains: how can we ensure early recognition and tailored treatment for PH patients? Share your thoughts in the comments below!
